Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Jul 11, 2022 5:35pm
169 Views
Post# 34816406

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Go to hell

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Go to hellI doubt this chart will show up once I hit post but it shows the quarterly sales trend for Egrifta and it is looking pretty sweet. I am glad they didn't give up on it as it is helping right now. I am not sure if they can keep it going but the trend is your friend with THTX's most profitable drug. 

The prospects for TH-1902 and the Sort1+platform are still what really matters as well as getting off a decent financing, but Egrifta is helping on the margin. If TH-1902 looks good, all should be easy on the financing front. If not, we will be glad we still have Egrifta. 



Trogarzon wrote: Don't know why but the first time 8 met Huss he discarded egrifta as a sidekick and wanted go after the statins instead with the coumpound or somthing like that.  Anyway he never had a chance to destroy the whole company like Paul is trying to with his ideas of grandeur.  Just the way he was commenting on the 500m market cap at the time.. like oh that thing like it did not matter... now that it's halved again he still doe'nt see it for what it is.. the only thing that matters to us shareholders... he's on a different quest than us my friends..


<< Previous
Bullboard Posts
Next >>